Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelly McNeil

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Clinical and Vaccine Immunology : CVI|January 21, 2011
Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trialMel Krajden, Darrel Cook, Amanda Yu, et al.
Vaccine|August 2, 2011
Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous doseScott A Halperin, Shelly McNeil, Joanne Langley, et al.
Vaccine|September 24, 2013
Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trialMel Krajden, Darrel Cook, Amanda Yu, et al.
Plos One|March 18, 2015
A new approach to improving healthcare personnel influenza immunization programs: a randomized controlled trialLarry W Chambers, Lois Crowe, Po-Po Lam, et al.
Emerging Infectious Diseases|May 2, 2013
Risk factors for influenza among health care workers during 2009 pandemic, Toronto, Ontario, CanadaStefan P Kuster, Brenda L Coleman, Janet Raboud, et al.
Journal of the Pediatric Infectious Diseases Society|September 4, 2015
Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialJoanne M Langley, Long Wang, Naresh Aggarwal, et al.
Journal of the American Geriatrics Society|October 25, 2016
T-Cell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home ResidentsJennie Johnstone, Robin Parsons, Fernando Botelho, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
Plos One|October 3, 2014
Immune biomarkers predictive of respiratory viral infection in elderly nursing home residentsJennie Johnstone, Robin Parsons, Fernando Botelho, et al.
BMC Public Health|May 4, 2019
Influenza epidemiology and influenza vaccine effectiveness during the 2016-2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)Víctor Baselga-Moreno, Svetlana Trushakova, Shelly McNeil, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Clinical and Vaccine Immunology : CVI|January 21, 2011
Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trialMel Krajden, Darrel Cook, Amanda Yu, et al.
Vaccine|August 2, 2011
Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous doseScott A Halperin, Shelly McNeil, Joanne Langley, et al.
Vaccine|September 24, 2013
Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trialMel Krajden, Darrel Cook, Amanda Yu, et al.
Plos One|March 18, 2015
A new approach to improving healthcare personnel influenza immunization programs: a randomized controlled trialLarry W Chambers, Lois Crowe, Po-Po Lam, et al.
Emerging Infectious Diseases|May 2, 2013
Risk factors for influenza among health care workers during 2009 pandemic, Toronto, Ontario, CanadaStefan P Kuster, Brenda L Coleman, Janet Raboud, et al.
Journal of the Pediatric Infectious Diseases Society|September 4, 2015
Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialJoanne M Langley, Long Wang, Naresh Aggarwal, et al.
Journal of the American Geriatrics Society|October 25, 2016
T-Cell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home ResidentsJennie Johnstone, Robin Parsons, Fernando Botelho, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
Plos One|October 3, 2014
Immune biomarkers predictive of respiratory viral infection in elderly nursing home residentsJennie Johnstone, Robin Parsons, Fernando Botelho, et al.
BMC Public Health|May 4, 2019
Influenza epidemiology and influenza vaccine effectiveness during the 2016-2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)Víctor Baselga-Moreno, Svetlana Trushakova, Shelly McNeil, et al.
Pageof 7